• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by MaxCyte Inc.

    5/29/25 4:30:10 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MXCT alert in real time by email
    DEFA14A 1 tm2516505d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant   x

     

    Filed by a Party other than the Registrant   ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    MaxCyte, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    xNo fee required

     

    ¨Fee paid previously with preliminary materials

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

    YOUR VOTE MATTERS

    PLEASE VOTE TODAY

     

    May 29, 2025

     

    Dear Stockholder:

     

    The 2025 Annual Meeting of Stockholders of MaxCyte, Inc. is scheduled to take place on Wednesday, June 18, 2025 at 11:00 a.m. Eastern Time. Our recent records show that you have not yet voted your shares. Your vote is very important. Please take one moment of your time to participate in this year’s meeting by voting your proxy today.

     

    Internet and telephone voting are available for your convenience and represent the most prompt methods to record your vote. Please follow the instructions on the proxy card or voting instruction form sent to you in order to vote electronically.

     

    OVERVIEW OF PROPOSALS TO BE PRESENTED AT THE ANNUAL MEETING

     

    Proposals Board Recommendation
    1. To elect the Board’s three nominees as identified in the accompanying Proxy Statement as Class I directors: Maher Masoud, Yasir Al-Wakeel, and Rekha Hemrajani “FOR” each director nominee
    2. To approve an amendment to the MaxCyte, Inc. 2022 Equity Incentive Plan to increase the number of shares of the Company’s common stock issuable thereunder by 2,950,000 shares “FOR”
    3. To approve the cancellation of admission to trading of the Company’s common stock on AIM, a securities trading market of the London Stock Exchange plc in the United Kingdom. “FOR”
    4. To ratify the Audit Committee’s selection of CohnReznick LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. “FOR”
    5. To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies. “FOR”

     

    Please vote your shares today. If you need assistance voting your shares, please contact our proxy solicitor, D.F. King & Co., Inc., toll free at (866) 796-7186 or via email at [email protected].

     

    On behalf of your Board of Directors, thank you for your participation and continued support.

     

    By Order of the Board of Directors

     

     

     

    David Sandoval
    Senior Vice President, General
    Counsel and Corporate Secretary

     

     

     

    Get the next $MXCT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MXCT

    DatePrice TargetRatingAnalyst
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$18.00Buy
    Stifel
    8/24/2021$22.00Buy
    BTIG
    More analyst ratings